Literature DB >> 12937950

The impact of image fusion in resolving discrepant findings between FDG-PET and MRI/CT in patients with gynaecological cancers.

Cheng-Chien Tsai1, Chien-Sheng Tsai, Koon-Kwan Ng, Chyong-Huey Lai, Swei Hsueh, Pan-Fu Kao, Ting-Chang Chang, Ji-Hong Hong, Tzu-Chen Yen.   

Abstract

This study was performed to prospectively investigate the impact of image fusion in resolving discrepant findings between fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) and magnetic resonance imaging (MRI) or X-ray computed tomography (CT) in patients with gynaecological cancers. Discrepant findings were defined as lesions where the difference between the FDG-PET and MRI/CT images was assigned a value of at least 2 on a 5-point probability scale. The FDG-PET and MRI/CT images were taken within 1 month of each other. Image fusion between FDG-PET and CT was performed by automatic registration between the two images. During an 18-month period, 34 malignant lesions and seven benign lesions from 32 patients who had undergone either surgical excision or a CT-guided histopathological investigation were included for analysis. Among these cases, image fusion was most frequently required to determine the nature and/or the extent of abdominal and pelvic lesions (28/41, 68%), especially as regards peritoneal seeding (8/41, 20%). Image fusion was most useful in providing better localisation for biopsy (16/41, 39%) and in discriminating between lesions with pathological versus physiological FDG uptake (12/41, 29%). Image fusion changed the original diagnosis based on MRI/CT alone in 9/41 lesions (22%), and the original diagnosis based on FDG-PET alone in 5/41 lesions (12%). It led to alteration of treatment planning (surgery or radiotherapy) in seven of the 32 patients (22%). In patients with gynaecological cancers, the technique of image fusion is helpful in discriminating the nature of FDG-avid lesions, in effectively localising lesions for CT-guided biopsy and in providing better surgical or radiotherapy planning.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937950     DOI: 10.1007/s00259-003-1300-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  42 in total

1.  PET/CT: a new road map.

Authors:  Peter J Ell; Gustav K von Schulthess
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-04-24       Impact factor: 9.236

2.  Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.

Authors:  Sang-Young Ryu; Moon-Hong Kim; Suck-Chul Choi; Chang-Woon Choi; Kyung-Hee Lee
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

3.  Computed tomography analysis of causes of local failure in radiotherapy for cervical carcinoma.

Authors:  S Suyama; T Nakaguchi; K Kawakami; K Shou; M Fushiki; M Taneike; A Matsui; M Takahashi; R Morita
Journal:  Cancer       Date:  1998-11-01       Impact factor: 6.860

4.  Image analysis in patients with cancer studied with a combined PET and CT scanner.

Authors:  M Charron; T Beyer; N N Bohnen; P E Kinahan; M Dachille; J Jerin; R Nutt; C C Meltzer; V Villemagne; D W Townsend
Journal:  Clin Nucl Med       Date:  2000-11       Impact factor: 7.794

5.  F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection.

Authors:  S M Bakheet; M Saleem; J Powe; A Al-Amro; S G Larsson; Z Mahassin
Journal:  Clin Nucl Med       Date:  2000-04       Impact factor: 7.794

6.  Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer.

Authors:  Lee A Zimmer; Barry McCook; Carolyn Meltzer; Melanie Fukui; Daphne Bascom; Carl Snyderman; David W Townsend; Jonas T Johnson
Journal:  Otolaryngol Head Neck Surg       Date:  2003-02       Impact factor: 3.497

7.  FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group.

Authors:  J F Vansteenkiste; S G Stroobants; P J Dupont; P R De Leyn; W F De Wever; E K Verbeken; J L Nuyts; F P Maes; J G Bogaert
Journal:  Eur J Nucl Med       Date:  1998-11

8.  Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG).

Authors:  K F Hubner; T W McDonald; J G Niethammer; G T Smith; H R Gould; E Buonocore
Journal:  Gynecol Oncol       Date:  1993-11       Impact factor: 5.482

9.  "Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity.

Authors:  R L Wahl; L E Quint; R D Cieslak; A M Aisen; R A Koeppe; C R Meyer
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

10.  High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue.

Authors:  S Yamada; K Kubota; R Kubota; T Ido; N Tamahashi
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

View more
  4 in total

1.  Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer?

Authors:  Yu-Chen Chang; Tzu-Chen Yen; Koon-Kwan Ng; Lai-Chu See; Chyong-Huey Lai; Ting-Chang Chang; Chien-Sheng Tsai; Ji-Hong Hong; Swei Hsueh; Hung-Hsueh Chou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-10       Impact factor: 9.236

2.  The role of 18F-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours: a pilot study.

Authors:  Ting Chang Chang; Tzu Chen Yen; Yiu Tai Li; Yen Ching Wu; Yu Cheng Chang; Koon Kwan Ng; Shih Ming Jung; Tzu I Wu; Chyong Huey Lai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-12       Impact factor: 9.236

3.  PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison.

Authors:  Marcelo A Queiroz; Rahel A Kubik-Huch; Nik Hauser; Bianka Freiwald-Chilla; Gustav von Schulthess; Johannes M Froehlich; Patrick Veit-Haibach
Journal:  Eur Radiol       Date:  2015-05-29       Impact factor: 5.315

4.  Comparison of integrated PET/MRI with PET/CT in evaluation of endometrial cancer: a retrospective analysis of 81 cases.

Authors:  Li-Hua Bian; Min Wang; Jing Gong; Hong-Hong Liu; Nan Wang; Na Wen; Wen-Sheng Fan; Bai-Xuan Xu; Ming-Yang Wang; Ming-Xia Ye; Yuan-Guang Meng
Journal:  PeerJ       Date:  2019-07-15       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.